Left ventricular assist device (LVAD) implantation is an established treatment for patients with end-stage, systolic heart failure as a bridge to heart transplantation or destination therapy. LVAD pump thrombosis is a life-threatening complication than can be triggered by prothrombotic conditions such as infection. Management of pump thrombosis presents as both a diagnostic and therapeutic challenge that is associated with a high morbidity and mortality. We report a case of pump thrombosis in a patient with a HeartMate II (Abbott Laboratories, Chicago, IL) and coronavirus (COVID-19) infection that was treated successfully with an intravenous thrombolytic, tissue plasminogen activator.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Jarrett, Simone A.; Alzubi, Jafar; Babapoor-Farrokhran, Savalan; Ammari, Zaid; Al-Sarie, Mohammad; Port, Zachary; Hasni, Farhan; Bozorgnia, Behnam; and Bonita, Raphael
"Left Ventricular Assist Device Thrombosis Treated with Intravenous Tissue Plasminogen Activator in a Patient with COVID-19 Infection,"
The VAD Journal: Vol. 7(1)
Available at: https://digitalcommons.library.tmc.edu/vad/vol7/iss1/6